Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

Summary

This is a single center, single arm Phase Ib study with expansion cohort designed to establish the safety and physiologic effects of sirolimus pre-conditioning followed by T-cell engaging bispecific antibody therapy.

Eligibility

Inclusion Criteria:

To be eligible to participate in this study, an individual must meet all of the following criteria:

* Willingness and ability to provide signed and dated informed consent form.
* Stated willingness to comply with all study procedures and availability for the duration of the study.
* Aged 18 years of older.
* Diagnosis with multiple myeloma, per IMWG Consensus Criteria.20
* Planned for treatment with teclistamab, or talquetamab per standard of care, label indications.15
* Prior exposure to any of the following types of T-cell engaging therapies.

  1. Anti-BCMA x CD3 bispecific antibody (for example: teclistamab, elranatamab)
  2. Anti-GPRC5d x CD3 bispecific antibody (for example: talquetamab)
  3. Anti-GPRC5d x CD3 x CD38 trispecific antibody
  4. Anti-BCMA x CD3 x CD38 trispecific antibody
  5. Anti-BCMA x CD3 x GPRC5d trispecific antibody
  6. Anti-BCMA chimeric antigen T-cell (for example: idecabtagene vicleucel, ciltacabtagene autoleucel)
  7. Anti-FcRL5 x CD3 bispecific antibody
* Required clinical laboratory values during screening phase

Hematologic Parameters Hemoglobin ≥7.0 g/dL; Platelets ≥25 x 109/L; Absolute Lymphocyte Count ≥0.2 x 109/L

Chemistries AST/ALT \< 5 x the ULN; Total Bilirubin \< 3 x the ULN

* Ability to take oral medication and be willing to adhere to the sirolimus pre-conditioning regimen.
* ECOG performance status of 0, 1, or 2 (KPS of \>50).
* For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner per section5.3.
* Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

* Participants whose multiple myeloma is progressing at a rapid pace requiring immediate anti-myeloma therapy per assessment by the principal investigator or enrolling investigator are excluded.
* Excluded concomitant medication exposures:

  * Exposure to corticosteroids within 1 week of treatment start
  * Exposure to calcineurin inhibitor or mTOR inhibitors (tacrolimus, everolimus, temsirolimus, sirolimus)
  * Immunomodulatory monoclonal antibodies targeting tumor necrosis factor alpha (e.g. infliximab), interleukin 6 (e.g. siltuximab),
  * Janus kinase inhibitors (e.g. ruxolitinib)
  * Any other investigational drug within 28 days
* History of allogeneic hematopoietic cell transplantation.
* Excluded concurrent medical conditions:

  * Active uncontrolled infection within 7 days prior to treatment start
  * Uncontrolled thrombotic event within 3 months of treatment start
  * Acute myocardial infarction or acute coronary syndrome within 6 months of start of treatment
  * Uncontrolled inflammatory bowel disease
  * Active hepatitis B virus, hepatitis C virus, or Human Immunodeficiency Virus infection
  * Uncontrolled rheumatologic conditions
  * Use of ACE-inhibitor therapy within 1 week of treatment start

    * Patients found to be taking ace-inhibitor therapy during screening can be included if the ace-inhibitor is substituted for an angiotensin receptor blocking agent. (https://drug-interactions.medicine.iu.edu/main-table)
    * CYP3A4/p-gp inhibitors and inducers for 7 days prior to sirolimus doses and 7 days after sirolimus doses(see appendix A for list)
  * Any other current active malignancy or history of metastatic malignancy that has the potential to interfere with the safety or efficacy assessment of the investigational intervention
* Pregnancy or lactation.
* Known allergic reactions to study agent (sirolimus).

Conditions2

Interventions3

Locations1 site

Related trials

• Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies — Federal Research Institute of Pediatric Hematology, Oncology and Immunology
• Methods of T Cell Depletion Trial (MoTD) — University of Birmingham
• Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia — Chinese SLE Treatment And Research Group
• The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus — Tongji Hospital
• Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study — Darcy Krueger
• 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome — City of Hope Medical Center
• The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation — National Cancer Institute (NCI)
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer — National Cancer Institute (NCI)

Browse More Trials